CRISPR-Drug Combinatorial Screening Identifies Effective Combination Treatments for MTAP-Deleted Cancer

Knoll N, Masser S, Bordas B, Ebright RY, Li G, Kesar D, Destefanis E, Kania N, Rodriguez DJ, Jen J, Zagar SE, Mensah C, Chen Z, Moffitt SJ, Enakireru EM, He Y, Feng B, Chokshi MK, Jin CY, Raghavan S, Sellers WR, Mulvaney KM.

Cancer Res, 2025

Early Clinical Success of MTA-Cooperative PRMT5 Inhibitors for the Treatment of CDKN2A/MTAP -Deleted Cancers.

Mulvaney, K. M.

Cancer Discov, 2023

Molecular basis for substrate recruitment to the PRMT5 methylosome.

Mulvaney, KM, Blomquist, C, Acharya, N, Li, R, Ranaghan, MJ, O’Keefe, M, Rodriguez, DJ, Young, MJ, Kesar, D, Pal, D, Stokes, M, Nelson, AJ, Jain, SS, Yang, A, Mullin-Bernstein, Z, Columbus, J, Bozal, FK, Skepner, A, Raymond, D, LaRussa, S, McKinney, DC, Freyzon, Y, Baidi, Y, Porter, D, Aguirre, A, Ianari, A, McMillan, B, Sellers, WR.

Molecular Cell, 2021

Discovery of a First-in-Class Inhibitor of the PRMT5–Substrate Adaptor Interaction.

McKinney, DC, McMillan, BJ, Ranaghan, MJ, Moroco, JA, Brousseau, M, Mullin-Bernstein, Z, O’Keefe, M, McCarren, P, Mesleh, M, Mulvaney, KM, Robinson, F, Singh, R, Bajrami, B, Wagner, FF, Hilgraf, R, Drysdale, MJ, Campbell, AJ, Skepner, A, Timm, DE, Porter, D, Kaushik, VK, Sellers, WR, Ianari, A.

Journal of Medicinal Chemistry, 2021

Loss of SWI/SNF Chromatin Remodeling Alters NRF2 Signaling in Non-Small Cell Lung Carcinoma. 

Song S, Nguyen V, Schrank T, Mulvaney K, Walter V, Wei D, Orvis T, Desai N, Zhang J, Hayes DN, Zheng Y, Major MB, Weissman BE. 

Mol Cancer Res, 2020

A conditional mouse expressing an activating mutation in NRF2 displays hyperplasia of the upper gastrointestinal tract and decreased white adipose tissue.

Bowman BM, Montgomery SA, Schrank TP, Simon JM, Ptacek TS, Tamir TY, Mulvaney KM, Weir SJ, Nguyen TT, Murphy RM, Makowski L, Hayes DN, Chen XL, Randell SH, Weissman BE, Major MB. 

J Pathol, 2020

Identification and Characterization of MCM3 as a Kelch-like ECH-associated Protein 1 (KEAP1) Substrate. 

Mulvaney KM, Matson JP, Siesser PF, Tamir TY, Goldfarb D, Jacobs TM, Cloer EW, Harrison JS, Vaziri C, Cook JG, Major MB.

J Biol Chem, 2016

Dissecting the Keap1/Nrf2 pathway through proteomics.

Tamir*, TY; Mulvaney, KM*; M. Ben Major.

Curr. Opin. Toxicol, 2017

Engineering a genetically encoded competitive inhibitor of the KEAP1-NRF2 interaction via structure-based design and phage display. 

Guntas G, Lewis SM, Mulvaney KM, Cloer EW, Tripathy A, Lane TR, Major MB, Kuhlman B.

Protein Eng Des Sel, 2016

Histone deacetylase inhibitors activate CIITA and MHC class II antigen expression in diffuse large B-cell lymphoma. 

Cycon KA, Mulvaney K, Rimsza LM, Persky D, Murphy SP.

Immunology, 2013

Proteomic analysis of ubiquitin ligase KEAP1 reveals associated proteins that inhibit NRF2 ubiquitination.

Hast BE, Goldfarb D, Mulvaney KM, Hast MA, Siesser PF, Yan F, Hayes DN, Major MB.

Cancer Res, 2013

Coordinate loss of MHC class II expression in the diffuse large B cell lymphoma cell line OCI-Ly2 is due to a novel mutation in RFX-AP. 

Bushway M, Cycon KA, Mulvaney K, Murphy SP.

Immunogenetics, 2010

Proteomic analysis of ubiquitin ligase KEAP1 reveals associated proteins that inhibit NRF2 ubiquitination.

Hast BE, Goldfarb D, Mulvaney KM, Hast MA, Siesser PF, Yan F, Hayes DN, Major MB.

Cancer Res, 2013

Identification and Characterization of MCM3 as a KEAP1 Substrate.

Mulvaney, KM.; Matson, J.; Siesser, P.; Tamir, TY; Goldfarb, D.; Jacobs, T.; Cloer, EW; Harrison, JS; Vaziri, C; Cook, JG; Major, MB.

Journal of Biological Chemistry, 2016